Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
Collapse
 
  • Page of 1
  • Filter
  • Time
  • Show
Clear All
new posts
Previous template Next
  • #1

    CDx success insights from Xalkori and Zelboraf

    4th Molecular Diagnostics for Cancer Drug Development
    Meet the oncology and diagnostics experts you need to deliver better, safer drugs to market quicker
    25 - 28 June 2012, Boston
    www.moleculardiagnostics-cancer.com

    Featuring 31 expert speakers, including:
    • Dr Richard Buller, Vice President, Translational Oncology, Pfizer
    • Dr Miu Chau, Global Head, Companion Diagnostics Operations, Genentech
    • Dr Mitch Raponi, Senior Director, Molecular Diagnostics & Translational Medicine, Clovis Oncology


    This meeting will profile those at the cutting edge of personalized medicine in oncology to give you a thorough review of best practice in end to end drug and diagnostic development from discovery to commercialization.

    For more information please visit the website: www.moleculardiagnostics-cancer.com or get in touch on [email protected].

    Josh Lowth
    Hanson Wade
    Tags: companion diagnostics, molecular diagnostics, oncology, personalized medicine
Previous template Next

Latest Articles

Collapse
  • seqadmin
    Current Approaches to Protein Sequencing
    by seqadmin


    Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
    04-04-2024, 04:25 PM
  • seqadmin
    Strategies for Sequencing Challenging Samples
    by seqadmin


    Despite advancements in sequencing platforms and related sample preparation technologies, certain sample types continue to present significant challenges that can compromise sequencing results. Pedro Echave, Senior Manager of the Global Business Segment at Revvity, explained that the success of a sequencing experiment ultimately depends on the amount and integrity of the nucleic acid template (RNA or DNA) obtained from a sample. “The better the quality of the nucleic acid isolated...
    03-22-2024, 06:39 AM
View All

ad_right_rmr

Collapse

News

Collapse
Topics Statistics Last Post
Cancer Metastasis: A Deep Dive into Cellular Plasticity by seqadmin
Started by seqadmin, 04-11-2024, 12:08 PM
0 responses
25 views
0 likes
 Last Post seqadmin
by seqadmin
04-11-2024, 12:08 PM  
Proteogenomic Profiles Offer New Clues in Prostate Cancer by seqadmin
Started by seqadmin, 04-10-2024, 10:19 PM
0 responses
29 views
0 likes
 Last Post seqadmin
by seqadmin
04-10-2024, 10:19 PM  
Novel Diagnostic Assay Enhances Ovarian Cancer Detection by seqadmin
Started by seqadmin, 04-10-2024, 09:21 AM
0 responses
25 views
0 likes
 Last Post seqadmin
by seqadmin
04-10-2024, 09:21 AM  
Evolutionary Dynamics of Centromeres: A Comparative Genomic Analysis by seqadmin
Started by seqadmin, 04-04-2024, 09:00 AM
0 responses
52 views
0 likes
 Last Post seqadmin
by seqadmin
04-04-2024, 09:00 AM  
View All
Working...
X